[1] 李祯, 生秀杰. 结肠癌转移相关基因1与肿瘤[J]. 国际肿瘤学杂志, 2013, 40(1):15-18.
[2] Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage Ⅱ and Ⅲ colon cancer: an assessment of their prognostic and oxaliplatin predictive value[J]. Clin Cancer Res, 2012, 18(23):6531-6541.
[3] Lagarde P, Pérot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors[J]. Clin Cancer Res, 2012, 18(3):826-838.
[4] Shull AY, Clendenning ML, GhoshalGupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients[J]. PLoS One, 2013, 8(3):e58731.
[5] Pagin A, Zerimech F, Leclerc J, et al. Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repairdeficient tumours[J]. Br J Cancer, 2013, 108(10):2079-2087.
[6] Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications[J]. Clin Cancer Res, 2012, 18(6):1506-1512.
[7] Pinheiro M, Ahlquist T, Danielsen SA, et al. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin[J]. BMC Cancer, 2010, 10:587-596.
[8] Chen W, Yuan L, Cai Y, et al. Identification of chromosomal copy number variations and novel candidate loci in hereditary nonpolyposis colorectal cancer with mismatch repair proficiency[J]. Genomics, 2013, 102(1):27-34.
[9] Fournier A, Sasai N, Nakao M, et al. The role of methylbinding proteins in chromatin organization and epigenome maintenance[J]. Brief Funct Genomics, 2012, 11(3):251-264.
[10] Walton EL, Francastel C, Velasco G. Maintenance of DNA methylation: Dnmt3b joins the dance[J]. Epigenetics, 2011, 6(11):1373-1377.
[11] Bae JM, Kim JH, Cho NY, et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location[J]. Br J Cancer, 2013, 109(4):1004-1012.
[12] Bae JM, Kim JH, Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype[J]. Histol Histopathol, 2013, 28(5):585-595.
[13] Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer[J]. N Engl J Med, 2009, 361(25):2449-2460.
[14] Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPICNorfolk study[J]. J Pathol, 2012, 228(3):405-415.
[15] Zhang T, Fields JZ, Opdenaker L, et al. Survivininduced AuroraB kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development[J]. Am J Pathol, 2010, 177(6):2816-2826.
[16] Lau T, Chan E, Callow M, et al. A novel tankyrase smallmolecule inhibitor suppresses APC mutationdriven colorectal tumor growth[J]. Cancer Res, 2013, 73(10):3132-3144.
[17] 侯庆生, 丁渭, 陈德喜. p53凋亡刺激蛋白2对饥饿诱导的大肠癌HCT116p53+/+细胞凋亡、周期和自噬的影响[J]. 国际肿瘤学杂志, 2013, 40(4):298-302.
[18] Yang W, Rozan LM, McDonald ER, et al. CARPs are ubiquitin ligases that promote MDM2independent p53 and phosphop53ser20 degradation[J]. J Biol Chem, 2007, 282(5):3273-3281.
[19] Muller PA, Vousden KH. p53 mutations in cancer[J]. Nat Cell Biol, 2013, 15(1):2-8.
[20] Pineda M, González S, Lázaro C, et al. Detection of genetic alterations in hereditary colorectal cancer screening[J]. Mutat Res, 2010, 693(1-2):19-31.
[21] Bellam N, Pasche B. Tgfbeta signaling alterations and colon cancer[J]. Cancer Treat Res, 2010, 155:85-103.
[22] Lee J, Ballikaya S, Schnig K, et al. Transforming growth factor beta receptor 2 (TGFBR2) changes sialylation in the microsatellite unstable (MSI) Colorectal cancer cell line HCT116[J]. PLoS One, 2013, 8(2):e57074.
[23] Shima K, Morikawa T, Yamauchi M, et al. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers[J]. PLoS One, 2011, 6(9):e25062.
[24] Fleming NI, Jorissen RN, Mouradov D, et al. Eppert K, SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer[J]. Cancer Res, 2013, 73(2):725-735.
[25] Stankic M, Pavlovic S, Chin Y, et al. TGFβId1 signaling opposes twist1 and promotes metastatic colonization via a mesenchymaltoepithelial transition[J]. Cell Rep, 2013, 5(5):12281242.
[26] Berlin J. Beyond exon 2—the developing story of RAS mutations in colorectal cancer[J]. N Engl J Med, 2013, 369(11):1059-1060.
[27] Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial[J]. J Natl Cancer Inst, 2013, 105(23):1789-1798.
[28] Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAFmutant colon cancer can be overcome with PI3K inhibition or demethylating agents[J]. Clin Cancer Res, 2013, 19(3):657-667. PMID: 23251002
[29] Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer[J]. Clin Cancer Res, 2012, 18(21):5856-5864. |